Thai Patent Authorities Await U.S. Compulsory Licensing Challenge Before WTO
This article was originally published in PharmAsia News
Thailand's patent authorities say they are bracing for a suit they expect to be filed by the United States before the World Trade Organization over the pharmaceutical compulsory-license dispute. A senior official of the Commerce Ministry says America is preparing a suit that alleges Thailand never discussed with patent holders its plan to abrogate drug patents so generic versions of certain drugs could be sold in the country. Thai officials dispute that claim, saying the government had negotiated with patent owners before compulsory licenses were announced. Drug makers offered only to lower their prices gradually. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.